Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East

Figure 3

CRP (a) and ESR (b) to week 24. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. (a) for all visits after baseline versus baseline, based on least square pairwise comparison. = number of patients with treatment administered at that visit. Follow-up visit for all patients. (b) for all visits after baseline versus baseline, based on least square pairwise comparison. = number of patients with treatment administered at that visit. Follow-up visit for all patients.

(a)

(b)